Answers are grounded in this paper and cite their sources.
Figure S3. Kaplan-Meier plot showed the PFS of patients diagnosed as CBF and non-CBF AML underwent dynamic monitoring of mutations by ctDNA from admission to the last cycle of chemotherapy. PFS, progression-free survival. CBF, core binding factor
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: